Civica Rx takes a step toward overhauling pharma supply chain; Alynylam therapy succeeds in closely watched trial

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Civica Rx begins selling its first outpatient generic drug as it tries to overhaul the pharmaceutical supply chain By Ed Silverman Adobe "There are warped incentives in our drug distribution channel," said Antonio Ciaccia, who heads 46brooklyn Research. Read More STAT+: Alnylam therapy for increasingly common heart disease succeeds in closely watched trial By Damian Garde Ruby Wallau for STAT The results clear the path to approval and affirm the promise of a drug analysts expect to reap blockbuster sales. Read More The trust-builder: a cancer center director's try-it-all strategy for breaking the barriers between research and Black patients By Angus Chen Carlos Bernate for STAT Black residents had reason to distrust the hospital at Virginia Commonwealth University. Robert Winn is building trust any way he can. Read More Sponsor content by STAT Events Biomarkers: The Foundation of Personalized Oncology Register for a virtual event on August 17 to hear researchers, academics, and business leaders discuss what recent innovations in biomarkers mean for the future of cancer treatments. Opinion: Lack of diversity in clinical trials costs billions of dollars. Incentives can spur innovation By Dana P. Goldman and Edith A. Perez and Carlos del Rio Adobe Incentives can nudge biopharma companies and contract research organizations to increase participant diversity in clinical trials. Read More Wednesday, August 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser